SLC5A2 and heart failure: The rapid divergence of survival curves with SGLT2 inhibitors in landmark trials on CHF, such as DAPA‐HF (Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction)15 and EMPEROR‐Reduced (Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure)1 highlighted their early clinical benefits.